Modulation of immune responses to hepatitis C virus envelope E2 protein following injection of plasmid DNA using single or combined delivery routes.
Different delivery routes of plasmid DNA may result in the induction of differential humoral and cellular immunity. We have studied the influence of two main routes of plasmid injection, performed intramuscularly and intraepidermally using a gene gun, for the induction of immune responses specific to hepatitis C virus (HCV) envelope protein E2. Three plasmids expressing different immunogenic domains of E2 (amino acids [aa] 384443, aa 504-555, and aa 384-746) were injected into BALB/c mice according to five different protocols using various combinations of intramuscular (i.m.) or intraepidermal (i.e.) primary and booster injections. Seroconversion rates, antibody titers and isotypes, epitope recognition, and T-helper (Th) release cytokine profiles were analyzed. Antibody titers and epitope recognition were linked to either or both the nature of the immunogen expressed and the delivery route chosen. In all cases, the lowest antibody titers were obtained using single i.m.-based protocols. Independently of the antibody titers generated, only some specific i.e.-combined delivery routes induced antibodies able to recognize determinants located in the N-terminal of E2 (aa 384411 and aa 411437) and mimicked by synthetic peptides. By contrast, the antibody isotypes and the splenic cytokine production identified were independent of the plasmids used and the delivery route implemented. All conditions resulted in Th-1 like responses suggested by the exclusive detection of IgG2a and 2b antibodies and the production of interferon gamma (INF-gamma) but no interleukin-4 (IL-4). Overall, our results suggest that the combination of i.m. and i.e. delivery routes provides the most efficient way to induce a broad immune response against HCV-E2.
Fournillier
A
A
INSERM U271, Virus des hépatites, Rétrovirus humains et Pathologies associées, Lyon, France.
Nakano
I
I
Vitvitski
L
L
Depla
E
E
Vidalin
O
O
Maertens
G
G
Trépo
C
C
Inchauspé
G
G
D000818:Animals; D000917:Antibody Formation / Q000502:physiology; D019470:Biolistics; D016207:Cytokines / Q000096:biosynthesis; D004279:DNA, Viral / Q000008:administration & dosage* / Q000494:pharmacology; D000939:Epitopes / Q000276:immunology; D005260:Female; D016174:Hepacivirus / Q000378:metabolism*; D018937:Hepatitis C Antibodies / Q000032:analysis; D007114:Immunization / Q000379:methods; D007267:Injections; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D051379:Mice; D008807:Mice, Inbred BALB C; D010957:Plasmids / Q000235:genetics*; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism
D016207:Cytokines; D004279:DNA, Viral; D000939:Epitopes; D018937:Hepatitis C Antibodies; D014759:Viral Envelope Proteins